Comorbid IBS Affects PPI Treatment for GERD

AUGUST 01, 2004

Patients with irritable bowel syndrome (IBS) frequently suffer from symptoms that are characteristic of gastroesophageal reflux disease (GERD), suggesting that comorbidity is not uncommon. It is not known, however, whether comorbid IBS in patients with GERD affects the efficacy of proton pump inhibitors (PPIs), which are typically used to treat patients with GERD.

A study conducted by William D. Chey, MD, and colleagues, presented at the 105th Annual Meeting of the American Gastroenterological Association and Digestive Disease Week (DDW), held from May 15 to 20, 2004, in New Orleans, La, examined the relationship between the presence of comorbid IBS and PPI efficacy in patients with GERD (n = 68). Results showed that patients with GERD and comorbid IBS have more severe GERD symptoms than do individuals with GERD alone. Also, patients with both GERD and IBS are more likely to experience residual GERD symptoms during PPI therapy than are those with GERD alone.


Become a Respimat Top Performer 

Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc. 

Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today? 


Pharmacy Times Strategic Alliance

Pharmacist Education
Clinical features with downloadable PDFs

Next-Generation Pharmacist® Awards

3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference

Personalize the information you receive by selecting targeted content and special offers.